Urinary and bowel disorders, manifesting as symptoms like frequent urination or difficulty in bowel movements, can greatly ...

Stryker has received 510(k) clearance for a minimally invasive back pain treatment, positioning it to challenge Boston Scientific for the market. The Food and Drug Administration clearance, which ...

Autonomix Medical, Inc. AMIX recently announced that it has been granted a key U.S. patent for its innovative catheter-based ...

In a new clinical study, researchers from the Texas Biomedical Device Center (TxBDC) at The University of Texas at Dallas ...

Neurons in a brain region linked with substance-use disorders can affect how much pain is felt when stopping chronic opioid ...

People with incomplete cervical spinal cord injuries showed improvements to their hand and arm movements after receiving a ...

University of Arizona Health Sciences researchers have identified a potential way to reduce female post-operative pain by ...

Stryker's OptaBlate system just scored 510(k) clearance from the FDA, marking a leap in nerve-targeting tech for spine pain.

Stryker’s OptaBlate, the company’s first basivertebral nerve ablation system earned FDA 510(k) clearance. OptaBlate is used for a minimally invasive, target procedure for chronic vertebrogenic low ...

Medical technology company Stryker Corp. (SYK) on Monday announced that its OptaBlate basivertebral nerve ablation system ...

Stryker announced today that it received FDA 510(k) clearance for its OptaBlate basivertebral nerve ablation system ...

Stryker said Monday that its OptaBlate basivertebral nerve ablation system received 510 (k) clearance from the Food and Drug Administration. The medical technology company said its OptaBlate BVNA is ...